(PDF) Successful Treatment With Osimertinib and

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.05.023

Full Text

Open PDF

Abstract

Available in full text

Date

November 1, 2018

Authors

Hironori Yoshida

Masahiro Ooi

Young Hak Kim

Publisher

Elsevier BV

Related search

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

English

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Current Oncology

Oncology

2012

English

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

English

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

English

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Treatment of EGFR Mutation–positive Non–small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report

Oncotarget

Oncology

2018

English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

English

Amanote Research

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.05.023

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Treatment of EGFR Mutation–positive Non–small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Amanote Research

Successful Treatment With Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient With EGFR Mutation and Meningeal Carcinomatosis

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.05.023

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Second-Line Erlotinib in an EGFR Mutation-Negative Patient With Non-Small-Cell Lung Cancer

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Severe Hepatotoxicity Due to Osimertinib After Nivolumab Therapy in Patients With Non‐small Cell Lung Cancer Harboring EGFR Mutation

P2.13-42 Osimertinib Treatment for Patients With EGFR Exon 20 Insertion Positive Non-Small-Cell Lung Cancer

Treatment of EGFR Mutation&#x2013;positive Non&#x2013;small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Treatment of EGFR Mutation–positive Non–small Cell Lung Cancer Complicated by Trousseau Syndrome With Gefitinib Followed by Osimertinib: A Case Report